Independent Clinical Study Results for the UltraShape™ Non-Invasive Fat Reduction and Body Contouring System to be Presented at the American Society For Plastic Surgeons Annual Meeting
Yoqneam, Israel and San Ramon, California - October 30, 2007 - Results of an independent multi-treatment clinical study of the UltraShape Contour I, the first clinically proven non-invasive focused ultrasound solution for fat reduction and body contouring, was presented at the American Society for Plastic Surgeons (ASPS) annual meeting on October 30, 2007 in Baltimore, MD. The presentation was entitled "Non-invasive Ultrasonic Selective Fat Cell Lysis and Body Contouring" and will take place during the scientific session "Body Contouring: Are We There Yet?"
London-based plastic surgeon, Chris Inglefield, BSC, FRCS (Plast), presented his two-and-one half years of clinical experience and results of his 118 patient clinical study using the UltraShape system to reduce localized fat deposits in the abdomen, flanks, hips, inner and outer thighs, back rolls, buttocks and male chest. Study participants received a series of three treatments, one month apart, which resulted in an average three-inch (7.5cm) reduction in circumference for all body areas, and an average 2.5-inch (6.3cm) reduction in circumference for the abdomen, hips and lateral thighs. The study also found that ninety-three percent (93%) of patients described their results as either "good" or "excellent." Additionally, there were no patient-related adverse events.
"The excellent patient satisfaction that I've seen with the UltraShape procedure over the past two years confirms that this technology is safe and effective, and answers an unmet patient need for non-invasive fat reduction with no pain or downtime," said Inglefield. "The convenient 'walk-in, walk-out' procedure allows patients to see measurable circumference reduction and body contouring without the hassle and risk associated with other, more invasive approaches - they literally receive the treatment and then immediately resume their daily routine."
The study, conducted at London Bridge Plastic Surgery in London, measured results of more than 118 women (n=86) and men (n=32) with a mean age of 38 years old. Selected patients had a body mass index of less then 30, a healthy, motivated attitude toward exercise and diet, localized fat deposits and a desire for non-invasive fat-reduction and body contouring.
"As we continue to add to our extensive body of clinical data for UltraShape we are encouraged by the positive response from both patients and physicians," said Rodger Stewart, President and Chief Executive Officer of UltraShape, Inc. "There is an increasing demand for non-invasive fat reduction and body contouring, and UltraShape offers a safe, effective option without downtime or required maintenance treatments."
About the UltraShape Contour I
The UltraShape Contour I system, based on patented focused ultrasound technology, is the first scientifically and clinically proven non-invasive fat reduction and body contouring solution for both men and women. The device produces mechanical, non-thermal, acoustic effects which targets and selectively destroys fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guarantees adherence to a pre-determined treatment algorithm minimizing risk of contour irregularities, a common side effect of liposuction. The UltraShape procedure is performed during a convenient, "walk-in, walk-out" session carried out in an office-based environment; it requires no anesthesia or sedation, and the vast majority of patients report no pain or discomfort. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape procedure is available in 47 countries and over 45,000 patient treatments have been performed worldwide with high patient satisfaction. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The UltraShape Contour I was selected as the Ultrasonic Industry Association's (UIA) New Product for 2007, an award recognizing its innovative use of ultrasound technology.
UltraShape is redefining aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for body contouring. The company is dedicated to providing clinically proven safe and effective solutions that enhance the lives of patients worldwide. The UltraShape proprietary non-invasive body contouring technology is based on focused ultrasound that targets and selectively disrupts fat cells without affecting surrounding structures. Founded in 2000, UltraShape is a privately held and venture backed company with offices in the United States, Israel, France, United Kingdom, and Italy.